Pasithea Therapeutics will reveal new data on its macrocyclic MEK inhibitor, PAS-004, at the European Society for Medical Oncology (ESMO) Congress in 2026. The presentation promises insight into therapies targeting the MAPK pathway for advanced solid tumors.

DS-3939, a new therapy candidate, is showing encouraging early-stage results in a Phase 1/2 trial targeting advanced solid tumors. While full details remain behind a paywall, initial findings from a recent announcement suggest possibilities for future cancer treatment options.